FMP
TherapeuticsMD, Inc.
TXMD
NASDAQ
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
0.725 USD
-0.0115 (-1.59%)
Historical Prices
From:
To:
About
ceo
Mr. Marlan D. Walker J.D.
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
exchange
NASDAQ
Description
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes b...
CIK
0000025743
ISIN
US88338N2062
CUSIP
88338N206
Address
951 Yamato Road
Phone
561 961 1900
Country
US
Employee
1
IPO Date
May 9, 2007
Financial Statement
Earnings
TXMD Financial Summary
CIK
0000025743
Exchange
NASDAQ
Industry
Drug Manufacturers -...
Sector
Healthcare
CUSIP
88338N206
ISIN
US88338N2062
Country
US
Price
0.73
Beta
1.18
Volume Avg.
576.73k
Market Cap
8.36M
Shares
-
52-Week
0.7-2.61
DCF
-1.83
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-2.07
P/B
-
Website
https://www.therapeuticsmd.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest TXMD News
Benzinga
Aug 26, 2024
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Bu...
The Dow Jones index closed higher by more than 450 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.
Zacks Investment Research
Apr 14, 2023
All You Need to Know About TherapeuticsMD (TXMD) Rating Upgr...
TherapeuticsMD (TXMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research
Nov 14, 2022
TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimate...
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research
Aug 15, 2022
TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimate...
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 29.28% and 23.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
Aug 15, 2022
TherapeuticsMD, Inc. (TXMD) CEO Hugh O'Dowd on Q2 2022 Resul...
TherapeuticsMD, Inc. (NASDAQ:TXMD ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 PM ET Company Participants Lisa Wilson - IR Hugh O'Dowd - CEO Michael Donegan - Interim CFO Mark Glickman - Chief Commercial Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Operator [Starts Abruptly] for the Therapeutics MD's Second Quarter 2022 Financial Results Conference Call.
Business Wire
Aug 8, 2022
TherapeuticsMD to Report Second Quarter 2022 Financial Resul...
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it will report its second quarter 2022 financial results on Monday, August 15, 2022, at 8:30 a.m. ET prior the opening of the U.S. financial markets. Executive management will host a conference call and webcast to discuss the results and provide a business update as follows: Date: Monday, August 15, 2022 Time: 8:30 a.m. ET
Benzinga
Jul 13, 2022
Why TherapeuticsMD Shares Are Sinking Today?
Women's healthcare company TherapeuticsMD Inc (NASDAQ: TXMD) shares are falling as EW Healthcare Partners did not acquire the required majority of shares of TXMD through the previously announced tender offer by the extended deadline. TherapeuticsMD's products are.
Market Watch
Jul 13, 2022
TherapeuticsMD's stock falls 41% after tender offer expires
Shares of TherapeuticsMD Inc. TXMD, +8.67% tumbled 41.6% in premarket trading on Wednesday after the women's health company told investors that EW Healthcare Partners' planned acquisition of TherapeuticsMD isn't expected to go through. The tender offer expired Tuesday.
